<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078973</url>
  </required_header>
  <id_info>
    <org_study_id>SAFA-1-2014</org_study_id>
    <secondary_id>2013-003800-38</secondary_id>
    <nct_id>NCT02078973</nct_id>
  </id_info>
  <brief_title>Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)</brief_title>
  <acronym>DOVA</acronym>
  <official_title>The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Circulatory System, During Basal Conditions and During Inhibition of the Nitric Oxide System in Healthy Subjects. A Dose-response Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and
      sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which
      stimulates V1-receptors in the vascular bed and may change both central and brachial
      hemodynamics and plasma concentration of vasoactive hormones.

      The purpose of the study is to measure the effects of tolvaptan on renal handling of water
      and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric oxide
      (NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CH2O</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of H2O clearance at baseline, during and after L-NMMA infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine biomarkers(Aquaporins and Epithelial Sodium Channels Î³)</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central and brachial blood pressure</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive Hormones( Angiotensin II, Aldosterone, Endothelin, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Arginin Vasopressin)</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional sodium excretion</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of Sodium excretion at baseline, during and after L-NMMA infusion.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>15 mg tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 15 mg tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 30 mg tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 45 mg tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of a Unikalk tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg tolvaptan</intervention_name>
    <description>15 mg pr day for 1 day</description>
    <arm_group_label>15 mg tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg tolvaptan</intervention_name>
    <description>30 mg pr day for 1 day</description>
    <arm_group_label>30 mg tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>45 mg tolvaptan</intervention_name>
    <description>45 mg pr day for 1 day</description>
    <arm_group_label>45 mg tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet Unikalk pr day for 1 day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Unikalk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, age 18-40 years

          -  Body Mass Index (BMI) 18,5-30 kg/m2

        Exclusion Criteria:

          -  Anamnestic or clinical signs of heart, lung, lever, kidney and brain disease

          -  Neoplastic disease

          -  Drug abuse

          -  Alcohol abuse

          -  Medical treatment except peroral anticontraceptive

          -  Pregnancy

          -  Smoking

          -  Abnormal blood and urine sample

          -  Abnormal ECG

          -  Blood donation within a month before examination

          -  Arterial hypertension (&gt;140 mmHg systolic and/or 90 mmHg diastolic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank H Mose, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of medical research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of medical research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2014</study_first_submitted>
  <study_first_submitted_qc>March 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD, Dr.Sci.</investigator_title>
  </responsible_party>
  <keyword>Tolvaptan</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>Nephrology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

